We are monitoring the impact of COVID-19 on MEA Leukemia Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Leukemia Therapeutics Market Research Report - Segmented By Disease Condition, Diagnosis, Treatments, Drugs & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 769
Pages: 145

MEA Leukemia Therapeutics Market Size & Growth (2022 to 2027)

The size of the Leukemia Therapeutics market in the Middle-East and Africa has been estimated at USD 0.59 Billion in 2022 and is projected to reach USD 0.92 Billion by 2027, at a CAGR of 9.23% during the forecast period from 2022 to 2027. 

Leukemia is a type of cancer where abnormal white blood cells crowd the bone marrow and other organs such as the liver, spleen, and kidneys through blood and prevent its normal functions. It is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. It is common in adults and is observed to progress with aging.

The factor that is driving the market for Leukemia Therapeutics in Middle-east and Africa is the simultaneous increase in increasing awareness about cancer treatments and drugs, along with increasing occurrence. Also, due to the increasing aging population, the market is driven, as the disease is common with aging.

But the market is feared to decline due to the high costs of treatment and drugs.

This research report on the MEA Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories

By Disease Condition:              

  • Chronic Lymphatic Leukemia           
  • Acute Lymphatic Leukemia              
  • Chronic Myeloid Leukemia               
  • Acute Myeloid Leukemia  

By Diagnosis:

  • CT scan     
  • Biopsy       
  • MRI            

By Treatments:

  • Chemotherapy      
  • Radiation therapy
  • Immunotherapy   
  • Surgery     
  • Targeted Therapy
  • Bone marrow transplant   
  • Stem Cell Therapy

By Drugs:

  • Gleevec    
  • Sapacitabine           
  • GA101       
  • Vasaroxine              
  • Tosedosat      

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.

Factors such as the rising prevalence of Leukemia, growing awareness of cancer screening programs, and raising awareness for healthcare among the population in developing nations of the region are making the companies penetrate into this market.

The leading companies leading in the MEA Leukemia Therapeutics market profiled in the report are F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods  

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Disease Condition                          

                             5.1.1 Chronic Lymphatic Leukemia         

                             5.1.2 Acute Lymphatic Leukemia             

                             5.1.3 Chronic Myeloid Leukemia             

                             5.1.4 Acute Myeloid Leukemia  

              5.2 By Diagnosis                           

                             5.2.1 CT scan    

                             5.2.2 Biopsy      

                             5.2.3 MRI          

              5.3 By Treatments                        

                             5.3.1 Chemotherapy     

                             5.3.2 Radiation therapy

                             5.3.3 Immunotherapy  

                             5.3.4 Surgery    

                             5.3.5 Targeted Therapy

                             5.3.6 Bone marrow transplant  

                             5.3.7 Stem Cell Therapy

              5.4 By Drugs                    

                             5.4.1 Gleevec    

                             5.4.2 Sapacitabine         

                             5.4.3 GA101      

                             5.4.4 Vasaroxine            

                             5.4.5 Tosedosat             

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 Middle-East                            

              6.3 Africa                         

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 F. Hoffmann-La Roche Ltd                 

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 GlaxoSmithKline Pharmaceuticals Limited                  

              9.3 Novartis International AG                  

              9.4 Bristol-Myers Squibb                          

              9.5 Eisai Co. Ltd              

              9.6 Biogen Idec               

              9.7 ERYtech Pharma                    

              9.8 Celgene Corporation                           

              9.9 Genmab A/S                           

              9.10 Cephalon Inc.                       

              9.11 Clavis Pharma                      

              9.12 Pfizer Inc.                

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  1. Middle East & Africa Leukemia Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Leukemia Therapeutics Market By Disease condition, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Cchronic Lymphatic Leukemia Market By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Acute Lymphatic Leukemia Market By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Chronic Myeloid Leukemia Market By Region, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Acute Myeloid Leukemia Market By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Leukemia Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Leukemia CT scan Market By Region, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Leukemia Biopsy Market By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Leukemia MRI Market By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Leukemia Therapeutics Market By Treatments, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Leukemia Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa Leukemia Radiation Therapy Market By Region, From 2022 - 2027 (USD Billion)
  14. Middle East & Africa Leukemia Immunotherapy Market By Region, From 2022 - 2027 (USD Billion)
  15. Middle East & Africa Leukemia Surgery Market By Region, From 2022 - 2027 (USD Billion)
  16. Middle East & Africa Leukemia Targeted Therapy Market By Region, From 2022 - 2027 (USD Billion)
  17. Middle East & Africa Leukemia Bone marrow transplant Market By Region, From 2022 - 2027 (USD Billion)
  18. Middle East & Africa Leukemia Stem Cell Therapy Market By Region, From 2022 - 2027 (USD Billion)
  19. Middle East & Africa Leukemia Therapeutics Market By Drugs, From 2022 - 2027 (USD Billion)
  20. Middle East & Africa Leukemia Gleevec Market By Region, From 2022 - 2027 (USD Billion)
  21. Middle East & Africa Leukemia Sepecitabine Market By Region, From 2022 - 2027 (USD Billion)
  22. Middle East & Africa Leukemia GA101 Market By Region, From 2022 - 2027 (USD Billion)
  23. Middle East & Africa Leukemia Vasaroxine Market By Region, From 2022 - 2027 (USD Billion)
  24. Middle East & Africa Leukemia Tosedosat Market By Region, From 2022 - 2027 (USD Billion)
  25. Middle East Leukemia Therapeutics Market By Disease condition, From 2022 - 2027 (USD Billion)
  26. Middle East Leukemia Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  27. Middle East Leukemia Therapeutics Market By Treatments, From 2022 - 2027 (USD Billion)
  28. Middle East Leukemia Therapeutics Market By Drugs, From 2022 - 2027 (USD Billion)
  29. Africa Leukemia Therapeutics Market By Disease condition, From 2022 - 2027 (USD Billion)
  30. Africa Leukemia Therapeutics Market By Diagnosis, From 2022 - 2027 (USD Billion)
  31. Africa Leukemia Therapeutics Market By Treatments, From 2022 - 2027 (USD Billion)
  32. Africa Leukemia Therapeutics Market By Drugs, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample